

Development of universal iPSC-NK (induced pluripotent stem cell-derived NK cell therapy) with higher ability of immune evasion and persistence for the treatment of solid cancer

Therabest Co., Ltd.



ONCOLOGY	Candidate
Product Type	Gene-edited iPSC-NK cell (Product for cell and gene therapy)
Indication	Progressive Liver cancer
Target	-
MoA(Mechanism of Action)	<ul style="list-style-type: none"> • NK cell-mediated cancer cell killing • IL-15RF K.I.: improving the persistence of iPSC-NK cell • B2M K.O. & HLA-G K.I.: enhancing the immune evasion capabilities of iPSC-NK cell
Competitiveness	First in Class
Development Stage	Candidate
Route of Administration	Intravenous